Anxiolytic-like effect of linezolid in experimental mouse models of anxiety

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 40, Issue 1, 2013, Pages 47-53

  Jindal, Ankur ^a   Mahesh, Radhakrishnan ^a   Kumar, Baldev ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Animal models; Anti anxiety; Linezolid; MAO A inhibitor

Indexed keywords

DIAZEPAM; LINEZOLID; MOCLOBEMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE COMPARISON; EXPERIMENTAL TEST; HEAD MOVEMENT; HOLE BOARD TEST; LATENT PERIOD; LIGHT DARK AVERSION TEST; MALE; MAZE TEST; MOUSE; NONHUMAN; TASK PERFORMANCE; TIME; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

ACETAMIDES; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; EMOTIONS; MALE; MICE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; OXAZOLIDINONES;

EID: 84867900402     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.09.006     Document Type: Article

References (48)

1. Aghajanian G.K., Sprouse J.S., Sheldon P., Rasmussen K. Electrophysiology of the central serotonin system: receptor subtypes and transducer mechanisms. Ann N Y Acad Sci 1990, 600:93-103.
2. Ament P.W., Jamshed N., Horne J.P. Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections. Am Fam Physician 2002, 65:663-670.
3. Beardslee S.L., Papadakis E., Fontana D.J., Commissaris R.L. Antipanic drug treatments: failure to exhibit anxiolytic-like effects on defensive burying behavior. Pharmacol Biochem Behav 1990, 35:451-455.
4. Biala G., Kruk M. Calcium channel antagonists suppress cross-tolerance to the anxiogenic effects of d-amphetamine and nicotine in the mouse elevated plus maze test. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:54-61.
5. Bortolato M., Chen K., Shih J.C. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 2008, 60:1527-1533.
6. Bortolato M., Godar S.C., Davarian S., Chen K., Shih J.C. Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice. Neuropsychopharmacology 2009, 34:2746-2757.
7. Caille D., Bergis O.E., Fankhauser C., Gardes A., Adam R., Charieras T., et al. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor II pharmacological profile. J Pharmacol Exp Ther 1996, 277:265-277.
8. Casarrubea M., Sorbera F., Crescimanno G. Multivariate analysis of the modifications induced by an environmental acoustic cue on rat exploratory behavior. Physiol Behav 2008, 93:687-696.
9. Cases O., Seif I., Grimsby J., Gaspar P., Chen K., Pournin S., et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 1995, 268:1763-1766.
10. De Angelis L. The effects of selective monoamine oxidases A or B inhibitors on the anxiogenic-like behaviour in mice. Biol Psychiatry 1997, 42:14-123. [Abstract].
11. De Angelis L., Furlan C. The anxiolytic-like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test. Pharmacol Biochem Behav 2000, 65:649-653.
12. Fraser A.D. Use and abuse of the benzodiazepines. Ther Drug Monit 1998, 20:481-489.
13. Golda V., Petr R. Validation of aversion towards open space and height as a measure of anxiety in the genetically based animal model of depression. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 1990, 33:513-527.
14. Greenblatt D.J., Shader R.I., Abernethy D.R. Drug therapy. Current status of benzodiazepines. N Engl J Med 1983, 309:410-416.
15. Johnston P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968, 17:1285-1297.
16. Johnston A.L., File S.E. Profiles of the antipanic compounds, triazolobenzodiazepines and phenelzine, in two animal tests of anxiety. Psychiatry Res 1988, 25:81-90.
17. Kelly D. Phenelzine in phobic states. Proc R Soc Med 1973, 66:949-950.
18. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:593-602.
19. Klodzinska A., Tatarczyńska E., Chojnacka-Wójcik E., Nowak G., Cosford N.D., Pilc A. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology 2004, 47:42-50.
20. Lader M., Morton S. Benzodiazepine problems. Br J Addict 1991, 86:823-828.
21. Liebowitz M.R., Fyer A.J., Gorman J.M., Campeas R., Levin A. Phenelzine in social phobia. J Clin Psychopharmacol 1986, 6:93-98.
22. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987, 92:180-185.
23. Low K., Crestani F., Keist R., Benke D., Brunig I., Benson J.A., et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000, 290:131-134.
24. Mahesh R., Jindal A., Gautam B., Bhatt S., Pandey D. Evaluation of anti-depressant-like activity of linezolid, an oxazolidinone class derivative - an investigation using behavioral tests battery of depression. Biochem Biophys Res Commun 2011, 409:723-726.
25. Mai A., Artico M., Esposito M., Ragno R., Sbardella G., Massa S. Synthesis and biological evaluation of enantiomerically pure pyrrolyloxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors. Farmaco 2003, 58:231-241.
26. Mi X.J., Chen S.W., Wang W.J., Wang R., Zhang Y.J., Li W.J., et al. Anxiolytic-like effect of paeonol in mice. Pharmacol Biochem Behav 2005, 81:683-687.
27. Moellering R.C. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003, 138:135-142.
28. Moise P.A., Forrest A., Birmingham M.C., Schentag J.J. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002, 50:1017-1026.
29. Paslawski T., Treit D., Baker G.B., George M., Coutts R.T. The antidepressant drug phenelzine produces antianxiety effects in the plus-maze and increases in rat brain GABA. Psychopharmacology 1996, 127:19-24.
30. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm entries in an elevated plus maze as a measure of anxiety in the rat. J Neurosci Methods 1985, 14:149-167.
31. Peppard W.J., Weigelt J.A. Role of linezolid in the treatment of complicated skin and soft tissue infections. Expert Rev Anti Infect Ther 2006, 4:357-366.
32. Popova N.K., Skrinskaya Y.A., Amstislavskaya T.G., Vishnivetskaya G.B., Seif I., de Meier E. Behavioral characteristics of mice with genetic knockout of monoamine oxidase type A. Neurosci Behav Physiol 2001, 31:597-602.
33. Priest R.G., Baldwin D.S., Bullock T., Kibel D., Smeyatsky N., Steinert J. Recent advances in antidepressant drugs. S Afr Med J 1992, 6(Suppl.):1-4.
34. Quinn D.K., Stern T.A. Linezolid and serotonin syndrome. Prim Care Companion J Clin Psychiatry 2009, 11:353-356.
35. Ramsay R.R., Gravestock M.B. Monoamine oxidases: to inhibit or not to inhibit. Mini Rev Med Chem 2003, 3:129-136.
36. Revelli A., Tesarik J., Massobrio M. Nongenomic effects of neurosteroids. Gynecol Endocrinol 1998, 12:61-67.
37. Roth M., Guelfi J.D. The efficacy of reversible monoamine oxidase inhibitors in depressive illness. Can J Psychiatry 1992, 37:18-24.
38. Shekhar A., McCann U.D., Meaney M.J., Blanchard D.C., Davis M., Frey K.A., et al. Summary of a National Institute of Mental Health workshop: developing animal models of anxiety disorders. Psychopharmacology (Berl) 2001, 157:327-339.
39. Shih J.C., Thompson R.F. Monoamine oxidase in neuropsychiatry and behavior. Am J Hum Genet 1999, 65:593-598.
40. Silva M.I., de Aquino Neto M.R., Teixeira Neto P.F., Moura B.A., do Amaral J.F., de Sousa D.P., et al. Central nervous system activity of acute administration of isopulegol in mice. Pharmacol Biochem Behav 2007, 88:141-147.
41. Swinkels J.A., de Jonghe F. Safety of antidepressants. Int Clin Psychopharmacol 1995, 9:19-25.
42. Takeda H., Tsuji M., Matsumiya T. Changes in head-dipping behavior in the hole board test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol 1998, 350:21-29.
43. Tyrer P., Candy J., Kelly D. Phenelzine in phobic anxiety: a controlled trial. Psychol Med 1973, 3:121-124.
44. van Broekhoven F., Kan C.C., Zitman F.G. Dependence potential of antidepressants compared to benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:939-943.
45. Wei X.Y., Yang J.Y., Wang J.H., Wu C.F. Anxiolytic effect of saponins from Panax quinquefolium in mice. J Ethnopharmacol 2007, 111:613-618.
46. Whiting P. GABA-A receptors: a viable target for novel anxiolytics?. Curr Opin Pharmacol 2006, 6:24-29.
47. Youdim M.B., Bakhle Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 2006, 147:S287-S296.
48. Zhang Y., Wang W., Zhang J. Effects of novel anxiolytic 4-butyl-alpha-agarofuran on levels of monoamine neurotransmitters in rats. Eur J Pharmacol 2004, 504:39-44.